ibrelyn 125 (palbociclib capsules 125mg)
duopharma hapi sdn. bhd. - palbociclib -
ibrance
pfizer new zealand limited - palbociclib 100mg - film coated tablet - 100 mg - active: palbociclib 100mg excipient: colloidal silicon dioxide crospovidone opadry green 03k110010 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.
ibrance
pfizer new zealand limited - palbociclib 125mg - film coated tablet - 125 mg - active: palbociclib 125mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.
ibrance
pfizer new zealand limited - palbociclib 75mg - film coated tablet - 75 mg - active: palbociclib 75mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.
ibrance capsules 125 mg
pfizer pharmaceuticals israel ltd - palbociclib - capsules - palbociclib 125 mg - palbociclib - ibrance is indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with:- an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or- fulvestrant in patients with disease progression following endocrine therapy
ibrance 100mg 100 mg
مستودع البتراء للمواد الطبية - petra drug store - palbociclib 100 mg - 100 mg
ibrance 125mg 125 mg
مستودع البتراء للمواد الطبية - petra drug store - palbociclib 125 mg - 125 mg
ibrance 75 mg
مستودع البتراء للمواد الطبية - petra drug store - palbociclib 75 mg - 75 mg
ibrance 75mg cápsulas
pfizer europe ma eeig - palbociclib - palbociclib....75,000 mg
ibrance 100 mg capsulas.
pfizer europe ma eeig - palbociclib - palbociclib....100,000 mg